Literature DB >> 16387707

Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases.

Debomoy K Lahiri1, De-Mao Chen, Preeti Lahiri, Steve Bondy, Nigel H Greig.   

Abstract

The aging brain shows selective neurochemical changes involving several neural cell populations. Increased brain metal levels have been associated with normal aging and a variety of diseases, including Alzheimer's disease (AD). Melatonin levels are decreased in aging, particularly in AD subjects. The loss of melatonin, which is synthesized by the pineal gland, together with the degeneration of cholinergic neurons of the basal forebrain and the deposition of aggregated proteins, such as the amyloid beta peptides (Abeta), are believed to contribute to the development of cognitive symptoms of dementia. Aging and its variants, such as AD, should be viewed as the result of multiple "hits," including alterations in the levels of Abeta, metals, cholinesterase enzymes, and neuronal gene expression. Herein, we present evidence in support of this theory, based on several studies. We discuss melatonin's neuroprotective function, which plays an important role in aging, prolongation of life span, and health in the aged individual. It interacts with metals and, in some cases, neutralizes their toxic effects. Dietary supplementation of melatonin restores its age-related loss. In mice, an elevated brain melatonin significantly reduced levels of potentially toxic Abeta peptides. Thus, compensation of melatonin loss in aging by dietary supplementation could well be beneficial in terms of reducing metal-induced toxicity, lipid peroxidation, and losses in cholinergic signaling. We propose that certain cholinesterase inhibitors and the NMDA partial antagonist memantine, which are FDA-approved drugs for AD and useful to boost central nervous system functioning, can be made more effective by their combination with melatonin or other neuroprotectants. Herein, we highlight studies elucidating the role of the amyloid pathway, metals, melatonin, and the cholinergic system in the context of aging and AD. Finally, melatonin is present in edible plants and walnuts, and consuming foodstuffs containing melatonin would be beneficial by enhancing the antioxidative capacity of the organisms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16387707     DOI: 10.1196/annals.1352.008

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  9 in total

Review 1.  Screening of treatment targets for Alzheimer's disease from the molecular mechanisms of impairment by β-amyloid aggregation and tau hyperphosphorylation.

Authors:  Lian-Feng Lin; Huan-Min Luo
Journal:  Neurosci Bull       Date:  2011-02       Impact factor: 5.203

2.  Biochemical studies in Normal Pressure Hydrocephalus (NPH) patients: change in CSF levels of amyloid precursor protein (APP), amyloid-beta (Aβ) peptide and phospho-tau.

Authors:  Balmiki Ray; Patricio F Reyes; Debomoy K Lahiri
Journal:  J Psychiatr Res       Date:  2010-09-09       Impact factor: 4.791

3.  Chagas' disease parasite-derived neurotrophic factor activates cholinergic gene expression in neuronal PC12 cells.

Authors:  Nsikan Akpan; Kacey Caradonna; Marina V Chuenkova; Mercio PereiraPerrin
Journal:  Brain Res       Date:  2008-04-10       Impact factor: 3.252

Review 4.  EGFRvIII-targeted vaccination therapy of malignant glioma.

Authors:  Bryan D Choi; Gary E Archer; Duane A Mitchell; Amy B Heimberger; Roger E McLendon; Darell D Bigner; John H Sampson
Journal:  Brain Pathol       Date:  2009-10       Impact factor: 6.508

5.  Antiamnesic Effects of Walnuts Consumption on Scopolamine-Induced Memory Impairments in Rats.

Authors:  Shaahin Harandi; Leila Golchin; Mehdi Ansari; Alireza Moradi; Mohammad Shabani; Vahid Sheibani
Journal:  Basic Clin Neurosci       Date:  2015-04

Review 6.  AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer's Disease.

Authors:  Yu Wang; Hao Wang; Hong-zhuan Chen
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

Review 7.  The role of acetylcholinesterase inhibitors such as neostigmine and rivastigmine on chronic pain and cognitive function in aging: A review of recent clinical applications.

Authors:  Jabril Eldufani; Gilbert Blaise
Journal:  Alzheimers Dement (N Y)       Date:  2019-06-04

8.  Trough Melatonin Levels Differ between Early and Late Phases of Alzheimer Disease.

Authors:  Chieh-Hsin Lin; Chih-Chiang Chiu; Hsien-Yuan Lane
Journal:  Clin Psychopharmacol Neurosci       Date:  2021-02-28       Impact factor: 2.582

Review 9.  Immune-pineal axis: nuclear factor κB (NF-kB) mediates the shift in the melatonin source from pinealocytes to immune competent cells.

Authors:  Regina P Markus; Erika Cecon; Marco Antonio Pires-Lapa
Journal:  Int J Mol Sci       Date:  2013-05-24       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.